COCP - Cocrystal Pharma Inc Stock Price, Fair Value and News

$1.03+0.02 (+1.98%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

COCP Price Action

Last 7 days

2.0%

Last 30 days

-5.5%

Last 90 days

-29.4%

Trailing 12 Months

-48.5%

COCP RSI Chart

COCP Valuation

Market Cap

14.2M

Price/Earnings (Trailing)

-1.47

Price/Sales (Trailing)

7.05

EV/EBITDA

-1.1

Price/Free Cashflow

-1.47

COCP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

COCP Fundamentals

COCP Revenue

Revenue (TTM)

2.0M

COCP Earnings

Earnings (TTM)

-9.7M

Earnings Growth (Yr)

58.51%

Earnings Growth (Qtr)

0.29%

COCP Profitability

EBT Margin

-479.05%

Return on Equity

-126.11%

Return on Assets

-92.58%

Free Cashflow Yield

-67.89%

COCP Investor Care

Shares Dilution (1Y)

35.49%

Diluted EPS (TTM)

-0.93

COCP Alerts

1 major insider buys recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2020	1.9M	1.9M	1.9M	2.0M
2019	3.8M	4.7M	5.6M	6.6M
2018	0	0	2.0M	2.9M
2016	100.0K	112.0K	1.0M	0
2015	6.2M	4.1M	2.1M	78.0K
2014	0	0	0	8.2M
2013	15.9M	12.9M	10.3M	0
2012	13.5M	15.8M	16.6M	17.3M
2011	14.6M	14.0M	13.4M	12.8M
2010	0	0	0	15.3M

Get all data in R, Python etc through our Historical Stock Data APIs

About Cocrystal Pharma Inc

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

CEO	Dr. Sam Lee Ph.D.
WEBSITE	cocrystalpharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	12

Cocrystal Pharma Inc Frequently Asked Questions

What is the ticker symbol for Cocrystal Pharma Inc? What does COCP stand for in stocks?

COCP is the stock ticker symbol of Cocrystal Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cocrystal Pharma Inc (COCP)?

As of Wed Dec 03 2025, market cap of Cocrystal Pharma Inc is 14.2 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of COCP stock?

You can check COCP's fair value in chart for subscribers.

Is Cocrystal Pharma Inc a good stock to buy?

The fair value guage provides a quick view whether COCP is over valued or under valued. Whether Cocrystal Pharma Inc is cheap or expensive depends on the assumptions which impact Cocrystal Pharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for COCP.

What is Cocrystal Pharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, COCP's PE ratio (Price to Earnings) is -1.47 and Price to Sales (PS) ratio is 7.05. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. COCP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cocrystal Pharma Inc's stock?

In the past 10 years, Cocrystal Pharma Inc has provided -0.422 (multiply by 100 for percentage) rate of return.